From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Most adverse events reported with topical GHK-Cu are limited to localized redness, tingling, or irritation
Personalized plan: dosing frequency (often weekly/bi-weekly, then reassess)
The process ensures purity and precise dosing, as administration is intravenous only and should be performed by trained healthcare personnel
2 ) in control animals angiogenic response with all tested parameters (number of VEGF, CD34 and FVIII positive elements (data obtained on hematoxylin-eosin stain were equal to FVIII presentation and are not presented)) consistently reached its peak at day 7
Wellness is a journey of consistency
